Glycopeptide resistance in staphylococci

Current Opinion in Infectious Diseases

Volumn 11, Issue 6, 1998, Pages 653-658

  Hiramatsu, Keiichi ^a   Hanaki, Hideaki ^a  

^a JUNTENDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

METICILLIN; POLYPEPTIDE ANTIBIOTIC AGENT; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ENTEROCOCCUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; REVIEW; STAPHYLOCOCCUS;

EID: 0032406480     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-199812000-00002     Document Type: Review

References (39)

1. Moellering RC. The specter of glycopeptide resistance: current trends and future considerations. Am J Med 1998; 104:3S-6S.
2. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997; 40:135-136. The first report of VRSA clinical strain (MIC = 8 mg/l). The strain was isolated from a Japanese patient who responded poorly to vancomycin therapy.
3. Hiramatsu K, Aritaka N, Hanaki H, Kawasaki S, Hosoda Y, Hori S, et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 1997; 350:1668-1671. This paper demonstrates that VRSA is generated from hetero-VRSA and proposes heterogeneity in vancomycin resistance as a cause of vancomycin therapeutic failure. Hetero-VRSA strains are already disseminated widely throughout Japan. They are not detectable by the commonly used routine susceptibility tests.
4. CDC. Reduced susceptibility of Staphylococcus aureus to vancomycin - Japan, 1996. MMWR 1997; 46:624-626.
5. CDC. Staphylococcus aureus with reduced susceptibility to vancomycin - United States, 1997. MMWR 1997; 46:765-766. American patients from whomVRSA (VISA) strains were isolated.
6. CDC. Update: Staphylococcus aureus with reduced susceptibility to vancomycin - United States, 1997. MMWR 1997; 46:813-815. American cases from whom VRSA (VISA) strains were isolated.
7. Flores PA, Gordon SM. Vancomycin-resistant Staphylococcus aureus: an emerging public health threat. Cleveland Clin J Med 1997; 64:527-532.
8. Ploy MC, Grelaud C, Martin C, de Lumley L, Denis F. First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital. Lancet 1998; 351:1212. A French patient from whom VRSA (VISA) was isolated.
9. Hiramatsu K Vancomycin resistance in staphylococci. Drug Resist Updates 1998; 1:135-150. This is a comprehensive historical review of glycopeptide resistance in staphylococci, including resistance mechanisms, detection, epidemiology and therapeutic options.
10. Hanaki H, Kuwahara-Arai K, Boyle-Vavra S, Daum RS, Labischinski H, Hiramatsu K. Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50. J Antimicrob Chemother 1998; 42:199-209. Activated cell wall synthesis is associated with reduced glycopeptide susceptibility of both hetero-VRSA and VRSA. VRSA differs from hetero-VRSA in that the cell wall of the former is twice as thick. PBP2 overexpression alone can raise teicoplanin resistance from an MIC level of 1 up to 8 mg/l, but vancomycin resistance is only raised marginally, from an MIC level of 1 up to 2 mg/l.
11. Hanaki H, Labischinski H, Inaba Y, Kondo N, Murakami H, Hiramatsu K. Increase in glutamine-non-amidated muropeptides in the peptidoglycan of vancomycin-resistant Staphylococcus aureus strain Mu50. J Antimicrob Chemother 1998; 42:315-320. When compared with hetero-VRSA strain Mu3, VRSA strain Mu50 is found to have a distinctive cell wall composition: increased murein monomer to dimer ratio and increased concentrations of glutamine-non-amidated murein components are present in Mu50. Greater vancomycin binding to the purified peptidoglycan of Mu50 than to that of Mu3 substantiates the 'affinity trapping mechanism' of glycopeptide antibiotics in S. aureus.
12. Sieradzki K, Villari P, Tomasz A. Decreased susceptibilities to teicoplanin and vancomycin among coagulase-negative methcillin-resistant clinical isolates of staphylococci. Antimicrob Agents Chemother 1998; 42:100-107. This is a detailed description of coagulase-negative staphylococcal clinical strains in the USA expressing low-level resistance to glycopeptides.
13. Howe RA, Bowker KE, Walsh TR, Feest TG, MacGowan AP. Vancomycin-resistant Staphylococcus aureus. Lancet 1998; 351:602. A hetero-VRSA isolate in the UK from a patient who responded poorly to vancomycin therapy is described.
14. Gulay Z, Atay T, Kucukguven M, Yulug N. Staphylococcus aureus strains heterogeneously resistant to vancomycin at a unversity hospital in Turkey. The 38th Interscience Conference on Antimicrobial Agents and Chemotherapy abstract No. C-136; 1998.
15. Hiramatsu K. Molecular evolution of MRSA. Microbiol Immunol 1998; 39:531-543.
16. Kuwahara-Arai K, Kondo N, Hori S, Tateda-Suzuki E, Hiramatsu K. Suppression of methicillin resistance in a mecA-containing premethicillin-resistant Staphylococcus aureus strain is caused by the mecl-mediated repression of PBP2' production. Antimicrob Agents Chemother 1996; 40:2680-2685.
17. Turco TF, Melko GP, Williams JR. Vancomycin intermediate-resistant Staphylococcus aureus. Ann Pharmacother 1998; 32:758-760.
18. Kaatz G, Seo SM, Dorman NJ, Lerner SA. Emergence of teicoplanin resistance during therapy of Staphylococcus aureus endocarditis. J Infect Dis 1990; 162:103-108.
19. Nourse C, Kaufmann M, Byrne M, Byrne C, Moylett E, Murphy H, Butler K. Clinical isolates of Staphylococcus epidermidis with reduced susceptibilities to teicoplanin in a paediatric hospital in Ireland. J Antimicrob Chemother 1998; 42:118-119.
20. Jones ME, Jones RN, Sader H, Verhoef J, Acar J. Current susceptibilities of staphylococci to glycopeptides determined as part of an international resistance surveillance programme. J Antimicrob Chemother 1998; 42:119-121.
21. Shlaes DM, Shlaes JH. Teicoplanin selects for Staphylococcus aureus that is resistant to vancomycin. Clin Infect Dis 1995; 20:1071-1072.
22. Markopulos E, Graninger W, Georgopoulos A. In-vitro selection of resistance to vancomycin and teicoplanin in Enterococcus faecium and Enterococcus faecalis compared with Staphylococcus epidermidis. J Antimicrob Chemother 1998; 41:43-47.
23. Shlaes DM, Shlaes JH, Vincent S, Etter L, Fey PD, Goering RV. Teicoplanin-resistant Staphylococcus aureus expresses a novel membrane protein and increases expression of penicillin-binding protein 2 complex. Antimicrob Agents Chemother 1993; 37:2432-2437.
24. Beauregard DA, Maguire AJ, Williams DH, Reynolds PE. Semiquantitation of cooperativity in binding of vancomycin-group antibiotics to vancomycin-susceptible and -resistant organisms. Antimicrob Agents Chemother 1997; 41:2418-2423.
25. Reynolds PE. Structure, biochiemistry and mechanism of action of glycopeptide antibiotics. Eur J Clin Microbiol Infect Dis 1989; 8:943-950.
26. Sieradzki K, Tomasz A. Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus. J Bacteriol 1997; 179:2557-2566.
27. Domaracki BE, Evans A, Preston KE, Fraimow RA, Venezia RA. Increased oxacillin activity associated with glycopeptides in coagulase-negative staphylococci. Eur J Clin Microbiol Infect Dis 1998; 17:143-150.
28. Sieradzki K, Roberts RB, Serur D, Margrave J, Tomasz A. Recurrent peritonitis in a patient on dialysis and prophylactic vancomycin. Lancet 1998; 351:880-881.
29. Tenover FC, Lancaster MV, Hill BC, Steward CD, Stocker SA, Hancock GA, et al. Characterization of staphylococci with reduced susceptibility to vancomycin and other glycopeptides. J Clin Microbiol 1998; 36:1020-1027. Commercially available susceptibility tests were evaluated for the defectability of glycopeptide-resistant S. aureus strains. Broth microdilution tests held a full 24 hours and commercial vancomycin agar screening plates are appropriate for the detection of VRSA.
30. Luria SE, Delbrück M. Mutations of bacteria from virus sensitivity to virus resistance. Genetics 1943; 28:491-511.
31. Hanaki H, Ohkawa S, Inaba Y, Hashimoto T, Hiramatsu K. Development of a medium (Mu-3) for detection of hetero-vancomycin-resistant MRSA (hetero-VRSA). The 38th Interscience Conference on Antimicrobial Agents and Chemotherapy abstract No. C-132; 1998. A novel detection method of hetero-VRSA based on antagonism between vancomycin and β-lactam antibiotics.
32. Johnson AP, James D. Continuing increase in invasive methicillin-resistant infection. Lancet 1997; 350:1710.
33. CDC. Interim guidelines for prevention and control of staphylococcal infection associated with reduced susceptibility to vancomycin. MMWR 1997; 46:626-635.
34. Wenzel RP, Edmond MB. Vancomycin-resistant Staphylococcus aureus: infection control considerations. Clin Infect Dis 1998; 27:245-251.
35. Matrai-Kovalskis Y, Greenberg D, Shinwell ES, Fraser D, Dagan R. Positive blood cultures for coagulase-negative staphylococci in neonates: does highly selective vancomycin usage affect outcome? Infection 1998; 26:85-92.
36. Rahman M. Alternatives to vancomycin in treating methicillin-resistant Staphylococcus aureus infections. J Antimicrob Chemother 1998; 41:325-328.
37. Linden PK. Clinical implications of nosocomial Gram-positive bacteremia and superimposed antimicrobial resistance. Am J Med 1998; 104:24S-33S.
38. Hiramatsu K. The emergence of Staphylococcus aureus with reduced susceptibility to vancomycin in Japan. Am J Med 1998; 104:7S-10S.
39. Tanaka M, Wada N, Mori-Kurosaka S, Chiba M, Sato K, Hiramatsu K. In-vitro activity of DU-6859a against methicillin-resistant Staphylococcus aureus isolates with reduced susceptibilities to vancomycin. J Anti-microb Chemother 1998; 42:552-553.